Session » Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research
- 4:00PM-5:30PM
-
Abstract Number: 1704
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
- 4:00PM-5:30PM
-
Abstract Number: 1699
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
- 4:00PM-5:30PM
-
Abstract Number: 1700
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
- 4:00PM-5:30PM
-
Abstract Number: 1703
Increased Mortality and Cardiovascular Events in Male Patients with Systemic Sclerosis: Left Ventricular Global Longitudinal Strain as Possible Screening Tool
- 4:00PM-5:30PM
-
Abstract Number: 1702
Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation
- 4:00PM-5:30PM
-
Abstract Number: 1701
Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines